Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 7/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | GAPDH | P04406 | 1/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 9/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1255879 | 0.88 | GAPDH (0.47) | KITGAPDHCACNA1HKDM4EF11 | |
| SCHEMBL18463666 | 0.87 | KIT (0.51) | KITFLT3GAPDHCACNA1H | |
| SCHEMBL18463706 | 0.87 | KIT (0.49) | KITFLT3 | |
| SCHEMBL16537266 | 0.87 | KIT (0.57) | KITFLT3 | |
| SCHEMBL1257209 | 0.84 | GAPDH (0.42) | KITGAPDHCACNA1HKDM4EF2 | |
| SCHEMBL18463667 | 0.84 | KIT (0.46) | KITFLT3 | |
| SCHEMBL1257770 | 0.83 | GAPDH (0.45) | KITGAPDHCACNA1HKDM4E | |
| SCHEMBL1256264 | 0.82 | KIT (0.56) | KITFLT3GAPDHCACNA1HKDM4E | |
| SCHEMBL1256308 | 0.82 | GAPDH (0.44) | KITFLT3GAPDHKDM4EF2 | |
| SCHEMBL1257268 | 0.79 | FLT3 (0.54) | FLT3GAPDHKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725465-B2 | Biaryl acetamide compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| EP-3039021-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2016-07-06 | — | — | EP | disclosed |
| US-20150065468-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2015-03-05 | — | — | US | disclosed |
| WO-2015031613-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2015-03-05 | — | — | WO | disclosed |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| EP-2467137-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011022473-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065468-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | ERBB2, ERBB3, AADAC | KIT 1109/4885FLT3 30/4885GAPDH 1574/4885 |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | FLT3, CSF3R, CSF1R | KIT 4/4885FLT3 1/4885GAPDH 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.